Prevention of ocular inflammation by matrine, prednisolone, and cyclooxygenase and lipoxygenase inhibitors.
Lens protein-induced ocular inflammation in rabbits was used to study the action mechanism of some anti-inflammatory agents. Indomethacin, a cyclooxygenase inhibitor, markedly reduced PGE2 and PGF2 alpha in the iris and ciliary body at 2 h but PGE2 only at 4 h. REV 5901, a lipoxygenase inhibitor, only significantly reduced PGE2 levels in the ciliary body at 4 h. PGF2 alpha levels were not affected by REV 5901. When indomethacin and REV 5901 were combined, both PGE2 and PGF2 alpha were suppressed at 2 and 4 h in both iris and ciliary body. Neither matrine nor prednisolone produced significant effects on the levels of PGE2 and PGF2 alpha. However, prednisolone exhibited the greatest reduction in chemotaxis of leukocytes followed by REV 5901. Indomethacin, on the contrary, produced a significant increase in chemotaxis of leukocytes. Matrine produced a decrease in leukocyte counts but was not statistically significant. These results indicate that indomethacin is effective in the early phase of inflammation to reduce PG's production whereas prednisolone and REV 5901 were more effective in the late phase of inflammation. Combined use of REV 5901 and indomethacin could become a drug of choice for the treatment of ocular inflammation without inducing corticosteroidal side effects.
Chang
M S
MS
Department of Medical Pharmacology & Toxicology, Texas A&M University College of Medicine, College Station 77843.
Xiao
J G
JG
Chiou
G C
GC
D000470:Alkaloids / Q000494:pharmacology*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D015237:Dinoprost / Q000096:biosynthesis; D015232:Dinoprostone / Q000096:biosynthesis; D009877:Endophthalmitis / Q000517:prevention & control*; D005260:Female; D007213:Indomethacin / Q000494:pharmacology*; D008084:Lipoxygenase; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D008297:Male; D011239:Prednisolone / Q000494:pharmacology*; D011804:Quinolines / Q000494:pharmacology*; D011807:Quinolizines; D011817:Rabbits; D000093842:Matrines
D000470:Alkaloids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D016859:Lipoxygenase Inhibitors; D011804:Quinolines; D011807:Quinolizines; C049740:alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol; D011239:Prednisolone; D015237:Dinoprost; D008084:Lipoxygenase; D015232:Dinoprostone; D007213:Indomethacin; D000093842:Matrines